Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Supercharged immune cells take on Hard-to-Treat cancers

NCT ID NCT05296564

Recruiting now Disease control Sponsor: Hadassah Medical Organization Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 32 times

Summary

This early-phase study tests a personalized cell therapy for people with several types of advanced cancer that have spread and express a protein called NY-ESO-1. Participants receive a single infusion of their own immune cells that have been genetically modified to recognize and attack cancer cells. The main goals are to check safety and see if tumors shrink.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hadassah Medical Organization

    RECRUITING

    Jerusalem, 9112001, Israel

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma melanoma metastatic malignant neoplasm metastatic melanoma Neoplasm Metastasis neuroblastoma non-small cell lung carcinoma ovarian cancer sarcoma soft tissue sarcoma synovial sarcoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER UROTHELIAL CARCINOMA MELANOMA STAGE IV MELANOMA STAGE IV METASTATIC CANCER NEUROBLASTOMA, METASTATIC NEUROBLASTOMA, METASTATIC NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER OVARY CANCER SARCOMA, SYNOVIAL SARCOMA,SOFT TISSUE TRIPLE NEGATIVE BREAST CANCER